Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab in Pediatric Solid Tumors
NCT02304458Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2015
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in solid tumor, neuroblastoma, osteosarcoma (OS), rhabdomyosarcoma (RMS), Ewing sarcoma, sponsored by National Cancer Institute. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
solid tumorneuroblastomaosteosarcoma (OS)rhabdomyosarcoma (RMS)Ewing sarcoma
Beyond the preview
Go deeper on NCT02304458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304458.